Determination of Regulatory Review Period for Purposes of Patent Extension; EXONDYS 51

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for the patent extension of EXONDYS 51, a human drug product, following the submission of applications to the US Patent and Trademark Office (USPTO). This determination is published as a notice, as required by law.